US Patent 11246913 Suspension formulation comprising an insulinotropic peptide
Patent 11246913 was granted and assigned to Intarcia Therapeutics, Inc. on February, 2022 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
June 14, 2019
0
Date of Patent
February 15, 2022
0
Patent Applicant
Patent Application Number
16441803
0
Patent Inventor Names
Thomas R. Alessi
0
Bing Yang
0
Catherine M. Rohloff
0
Ryan D. Mercer
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11246913 Suspension formulation comprising an insulinotropic peptide
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.